ValuEngine upgraded shares of Alliqua Biomedical (NASDAQ:ALQA) from a sell rating to a hold rating in a report issued on Thursday.

Separately, HC Wainwright lowered Alliqua Biomedical from a buy rating to a neutral rating and dropped their price target for the stock from $4.50 to $2.80 in a research note on Monday, January 8th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $8.20.

Shares of Alliqua Biomedical (ALQA) opened at $1.87 on Thursday. Alliqua Biomedical has a 12 month low of $1.58 and a 12 month high of $8.48.

TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with's FREE daily email newsletter.